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ABSTRACT
Oxysterols are oxidised derivatives of cholesterol, formed by the enzymatic 
activity of several cytochrome P450 enzymes and tumour-derived oxysterols have 
been implicated in tumour growth and survival. The aim of this study was to profile 
the expression of oxysterol metabolising enzymes in primary colorectal cancer and 
assess the association between expression and prognosis.
Immunohistochemistry was performed on a colorectal cancer tissue microarray 
containing 650 primary colorectal cancers using monoclonal antibodies to CYP2R1, 
CYP7B1, CYP8B1, CYP27A1, CYP39A1, CYP46A1 and CYP51A1, which we have 
developed. Unsupervised hierarchical cluster analysis was used to examine the overall 
relationship of oxysterol metabolising enzyme expression with outcome and based on 
this identify an oxysterol metabolising enzyme signature associated with prognosis.
Cluster analysis of the whole patient cohort identified a good prognosis group 
(mean survival=146 months 95% CI 127-165 months) that had a significantly 
better survival (c2=12.984, p<0.001, HR=1.983, 95% CI 1.341-2.799) than the 
poor prognosis group (mean survival=107 months, 95% CI 98-123 months). For 
the mismatch repair proficient cohort, the good prognosis group had a significantly 
better survival (c2=8.985, p=0.003, HR=1.845, 95% CI 1.227-2.774) than the poor 
prognosis group. Multi-variate analysis showed that cluster group was independently 
prognostically significant in both the whole patient cohort (p=0.02, HR=1.554, 95% 
CI 1.072-2.252) and the mismatch repair proficient group (p=0.04, HR=1.530, 95% 
CI 1.014-2.310).
Individual oxysterol metabolising enzymes are overexpressed in colorectal 
cancer and an oxysterol metabolising enzyme expression profile associated with 
prognosis has been identified in the whole patient cohort and in mismatch repair 
proficient colorectal cancers.
INTRODUCTION
Colorectal cancer is one of the most common 
types of malignancy affecting both men and women, 
with a worldwide annual incidence of greater than 1.2 
million new cases [1, 2]. The disease remains a leading 
cause of cancer-related mortality and, despite gradual 
improvements in prognosis, the 5-year survival remains 
relatively poor at approximately 55% [1]. Colorectal 
cancer develops slowly over several years and symptoms 
often only become apparent in the late stages, therefore 
many colorectal cancers present at an advanced stage. 
Patients presenting with distant metastatic disease have a 
5-year survival of less than 10% [1].
Currently, colorectal cancer is commonly staged 
using the tumour, node, metastasis (TNM) staging system 
to guide treatment decisions and indicate prognosis. 
However, patients with the same stage of tumour often 
experience a wide range of different clinical outcomes. 
Despite the unequivocal value of current staging systems, 
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there is a still need to develop reliable biomarkers to more 
accurately predict prognosis and risk stratify patients with 
colorectal cancer. Biomarkers can have a variety of roles 
in colorectal cancer including early detection, predicting 
prognosis, predicting response to therapy and aiding post-
operative monitoring [3].
Oxysterols are oxidised derivatives of cholesterol, 
formed by the enzymatic activity of several cytochrome 
P450 enzymes [4, 5]. Oxysterols function as key 
signalling molecules involved in the development and 
functioning of the immune system and the maintenance 
of cellular cholesterol homeostasis [6-12]. In addition 
to the established role of oxysterols in normal immune 
system functioning, it is increasingly acknowledged that 
the oxysterol pathway plays a role in tumourigenesis 
through altering host anti-tumour immunity. For example, 
oxysterols have been demonstrated to down-regulate the 
G-protein coupled receptor chemokine receptor 7 (CCR7) 
through activation of the ligand-activated transcription 
factor LXRα in dendritic cells [13]. CCR7 is involved in 
the migration of dendritic cells to draining lymph nodes, 
thus suppression of this chemokine receptor results in 
trapping of dendritic cells in the tumour and subsequent 
interference with antigen presentation to anti-tumour 
T-cells [7]. Through suppression of CCR7 in an LXR-
dependent manner, oxysterols impede host anti-tumour 
immunity. A further mechanism whereby oxysterols may 
promote tumour progression is via chemo-attraction of 
neutrophils [14, 15]. Invading neutrophils may provide 
a critical growth and survival advantage in many solid 
tumours due to production of the pro-angiogenic factors 
prokineticin-2 and matrix metalloproteinase-9 [16].
Despite the recognition of the role of oxysterol 
signalling in tumourigenesis, the key cytochrome P450s 
involved in the oxysterol pathway have received very 
limited study in existing research with regard to their 
expression in tumours [17, 18]. This study has profiled 
the expression of the cholesterol metabolising enzymes 
CYP2R1, CYP7B1, CYP8B1, CYP27A1, CYP39A1, 
CYP46A1 and CYP51A1 in primary colorectal cancer 
tissue using a well-characterised cohorts of colorectal 
cancers. The clinico-pathological significance of each of 
the cytochrome P450s studied was determined, including 
the relationship between expression and overall survival. 
An oxysterol metabolising enzyme expression profile 
associated with prognosis has been identified in the whole 
patient cohort and in mismatch repair proficient colorectal 
cancers.
RESULTS
Monoclonal antibodies to oxysterol metabolising 
enzymes
The specificity of the monoclonal antibodies to 
CYP2R1, CYP7B1, CYP8B1, CYP27A1, CYP39A1, 
CYP46A1 and CYP51A1 was determined by ELISA using 
the immunogenic peptides and also by immunoblotting 
using whole cell lysates from cells overexpressing of 
each protein (Figure 1). A band migrating at the expected 
molecular weight was observed for each antibody 
in a lysate prepared from cells overexpressing the 
relevant protein while no bands were detected with the 
corresponding control lysate.
Expression of oxysterol metabolising enzymes in 
primary and metastatic colorectal cancer
Each antibody showed immunoreactivity in normal 
colonic epithelium, primary colorectal cancer and 
metastatic colorectal cancer. Where immunoreactivity was 
observed, immunostaining was localised to the tumour cell 
cytoplasm (Figure 2). Nuclear or membranous staining 
was not observed. Whole section immunohistochemistry 
Figure 1: Immunoblots of CYP2R1, CYP7B1, CYP8B1, CYP27A1, CYP39A1, CYP46A1 and CYP51A1 monoclonal 
antibodies. The left hand lane (-) of each panel contains control cell lysate while the right hand lane (+) of each panel contains lysate 
prepared from cells over expressing the relevant protein. Fifteen micrograms of protein were loaded per well except CYP51A1 (five 
micrograms of protein). No bands were detected with the control lysate, while a band migrating at the expected molecular weight was 
observed for each antibody in the lane containing the relevant expressed protein.
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Figure 2: Photomicrographs of CYP2R1, CYP7B1, CYP8B1, CYP27A1, CYP39A1, CYP46A1 and CYP51A1 in 
normal colonic mucosa, primary colorectal cancer and metastatic colorectal cancer (original magnification x 300, 
scale bar represents 100μm).
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of a sub-set of tumours showed no evidence of intra-
tumour heterogeneity of expression of any of the oxysterol 
metabolising enzymes.
A general trend of increased expression in primary 
tumour cells compared to normal colonic mucosa was 
observed for all proteins studied (Figure 3). Furthermore, 
expression of each oxysterol metabolising enzyme was 
slightly reduced in lymph node metastasis compared 
to primary tumour. Immunostaining for CYP7B1 in 
primary tumours showed the highest proportion of strong 
immunostaining, with 62.8% of primary colorectal cancers 
displaying strong immunoreactivity for this target protein. 
Immunostaining for CYP46A1 showed 27.7% of primary 
tumours were strongly stained. Strong immunostaining 
for CYP51A1 was demonstrated in 21.9% of tumours and 
CYP8B1 immunoreactivity was classified as strong in 
18.9% of tumours. The remaining target proteins had very 
low frequencies of strong immunostaining and no tumour 
showed strong CYP39A1 immunoreactivity.
The intensity of immunostaining was significantly 
higher in primary colorectal cancer compared with 
normal colonic mucosa for CYP2R1 (p<0.001), CYP7B1 
(p<0.001), CYP8B1 (p<0.001), CYP46A1 (p<0.001) and 
CYP51A1 (p=0.001). CYP27A1 and CYP39A1 showed 
no statistically significant difference in expression between 
primary tumour and normal colonic mucosa (Table 1).
When examining the difference in expression 
between all cases of primary colorectal cancer and lymph 
node metastasis CYP7B1 (p=0.035), CYP39A1 (p=0.001), 
CYP46A1 (p<0.001) and CYP51A1 (p<0.001) each 
showed a significant decrease in immunoreactivity in 
lymph node metastasis compared to primary tumour. There 
was no statistically significant difference in expression of 
CYP7B1 or CYP27A1 between the paired cases of Dukes 
C (stage 3) colorectal cancer and their corresponding 
lymph node metastasis. However, CYP2R1 (p=0.034), 
CYP8B1 (p=0.002), CYP39A1 (p<0.001), CYP46A1 
(p<0.001) and CYP51A1 (p=0.001) each demonstrated 
significantly reduced expression in paired lymph node 
metastasis compared to Dukes C (stage 3) colorectal 
cancer.
Relationship of individual oxysterol metabolising 
enzymes with clinico-pathological parameters
The relationship between expression of each 
protein and relevant clinico-pathological parameters are 
summarised in Table 2. Expression of CYP2R1, CYP8B1, 
CYP27A1, CYP39A1 and CYP46A1 showed significant 
associations with Dukes stage. CYP39A1 and CYP46A1 
were also significantly associated with tumour stage 
and lymph node stage. CYP7B1, CYP8B1, CYP39A1, 
CYP46A1 and CYP51A1 each displayed a statistically 
significant relationship with location of tumour in the 
colon versus the rectum. When the anatomical site of 
the tumour was stratified as proximal colon, distal colon 
or rectum, significant associations were found with 
expression of CYP8B1, CYP27A1 and CYP51A1. When 
investigating the relationship between expression of each 
protein and the presence of extramural venous invasion, 
CYP8B1, CYP27A1, CYP39A1 and CYP46A1 showed 
correlations with this pathological variable. In addition 
to extramural venous invasion, CYP27A1 was also 
associated with mismatch repair protein status. Expression 
of CYP51A1 was associated with tumour differentiation 
and mismatch repair protein status.
Unsupervised hierarchical cluster analysis and 
identification of prognostic signature
Unsupervised hierarchical cluster analysis was used 
as an unbiased exploratory statistical tool to examine the 
overall relationship of oxysterol metabolising enzyme 
expression with outcome and based on this identify an 
oxysterol metabolising enzyme signature associated 
with prognosis. A range of cluster solutions (number 
of clusters) was investigated to determine the optimum 
number of clusters that produced groups with different 
outcomes. Clustering the data into five clusters was 
identified as the optimum number of clusters for analysis 
in relation to the most prognostically significant groups 
(Figure 4). These five clusters were then combined into 
two groups; a good prognosis group (group 1, cluster 
1) and a poor prognosis group (group 2, cluster 2-5) 
(Figures 4 and 5). The relationship of each cluster group 
and pathological parameters is shown in Table 3 and 
the expression of each oxysterol metabolising enzyme 
in each cluster group is shown in Table 4. The good 
prognosis group showed contained with low expression 
of CYP2R1 (p=0.002), CYP8B1 (p<0.001), CYP27A1 
(p=0.028) and CYP46A1 (p<0.001) relative to the poor 
prognosis group.
The good prognosis group (mean survival=146 
months, 95% CI 127-165 months, n=105, number of 
deaths=32) had a significantly better survival (χ2=12.984, 
p<0.001, HR=1.983, 95% CI 1.341-2.799) than the poor 
prognosis group (mean survival=107 months, 95% CI 98-
123 months, n=487, number of deaths=254) (Figure 5).
For the mismatch repair proficient cohort good 
prognosis group (mean survival=134 months, 95% 
CI 116-152 months, n=87, number of deaths=26) had 
a significantly better survival (χ2=8.985, p=0.003, 
HR=1.845, 95% CI 1.227-2.774) than the poor prognosis 
group (mean survival=110 months, 95% CI 107-126 
months, n=410, number of deaths=206).
For the mismatch repair deficient cohort good 
prognosis group (mean survival=131 months, 95% CI 87-
176 months, n=14, number of deaths=5) had a significantly 
better survival (χ2=2.518, p=0.113, HR=2.080, 95% 
CI 0.819-5.279) than the poor prognosis group (mean 
survival=84 months, 95% CI 76-113 months, n=70, 
number of deaths=42).
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Figure 3: The frequency distribution of the intensity of expression of CYP2R1, CYP7B1, CYP8B1, CYP27A1, 
CYP39A1, CYP46A1 and CYP51A1 in normal colonic mucosa, primary colorectal cancer and lymph node metastasis.
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Multi-variate analysis
Multi-variate analysis showed that cluster group 
was independently prognostically significant in both 
the whole patient cohort (p=0.02, HR=1.554, 95% CI 
1.072-2.252) and the mismatch repair proficient group 
(p=0.04, HR=1.530, 95% CI 1.014-2.310) in a model that 
included information about Dukes stage (Table 5, Model 
A). Multi-variate analysis also showed that cluster group 
was independently prognostically significant in the whole 
patient cohort (p=0.033, HR=1.497, 95% CI 1.032-2.172) 
and not the mismatch repair proficient cohort in a model 
that contained tumour stage and lymph node stage (Table 
6, Model B). Multi-variate analysis was also performed 
using only parameters that would be available at the 
time of a biopsy of colorectal cancer i.e. no pathological 
Table 1: Comparison of the expression of each oxysterol metabolising protein in normal colonic mucosa, primary 
colorectal cancer and lymph node metastasis
Immunoreactivity 
(p value, normal 
versus primary 
tumour)
Change in 
expression 
in tumour
Immunoreactivity 
(p value, primary 
tumour versus 
lymph node 
metastasis)
Change in 
expression in 
lymph node
Immunoreactivity 
(p value, paired 
primary Dukes 
C tumour versus 
lymph node 
metastasis)
Change in 
expression in 
lymph node
CYP2R1 p<0.001 ↑ p=0.172 - p=0.034 ↓
CYP7B1 p<0.001 ↑ p=0.035 ↓ p=0.116 -
CYP8B1 p<0.001 ↑ p=0.106 - p=0.002 ↓
CYP27A1 p=0.517 - p=0.108 - p=0.960 -
CYP39A1 p=0.714 - p=0.001 ↓ p<0.001 ↓
CYP46A1 p<0.001 ↑ p<0.001 ↓ p<0.001 ↓
CYP51A1 p=0.001 ↑ p<0.001 ↓ p=0.001 ↓
Evaluation of normal colonic epithelium versus primary tumour samples for immunoreactivity (Mann-Whitney U test, ↑ = 
increased in tumour, ↓ = decreased in tumour, -= no change between tumour and normal) and evaluation of primary Dukes 
C colorectal tumour samples and their corresponding metastasis samples for immunoreactivity (Wilcoxon signed rank sum 
test, ↑= increased in lymph node metastasis, ↓ = decreased in lymph node metastasis, -= no change between primary and 
metastatic tumour). Significant values are highlighted in bold.
Table 2: The relationship between expression of each oxysterol metabolising enzyme and pathological parameters
Screen 
detected  
(yes v no)
Tumour site  
(colon v 
rectum)
Tumour site 
(proximal 
colon v distal 
colon v 
rectum)
Tumour 
differentiation 
(well/
moderate v 
poor)
EMVI 
(present or 
absent)
Mismatch 
repair 
protein status 
(proficient  
v deficient)
Tumour stage Lymph node 
stage
Dukes stage
χ2 p-value χ2 p-value χ2 p-value χ2 p-value χ2 p-value χ2 p-value χ2 p-value χ2 p-value χ2 p-value
CYP2R1 1.564 0.668 0.690 0.876 10.940 0.090 3.492 0.322 2.186 0.535 5.296 0.151 21.225 0.012 10.061 0.122 13.142 0.041
CYP7B1 4.147 0.246 8.004 0.046 8.515 0.203 3.231 0.357 0.305 0.959 5.446 0.142 5.241 0.813 8.267 0.219 7.359 0.289
CYP8B1 1.111 0.774 19.712 <0.001 21.593 0.001 4.502 0.212 8.577 0.035 0.785 0.853 7.536 0.581 32.766 <0.001 29.844 <0.001
CYP27A1 3.207 0.361 4.189 0.242 21.394 0.002 2.866 0.413 16.318 0.001 10.009 0.018 14.085 0.119 11.048 0.087 13.555 0.035
CYP39A1 12.651 0.002 7.851 0.020 8.357 0.079 0.271 0.873 12.643 0.002 0.120 0.942 16.766 0.010 39.193 <0.001 32.463 <0.001
CYP46A1 2.139 0.544 8.657 0.034 12.308 0.055 1.378 0.711 7.964 0.047 4.664 0.198 19.288 0.023 16.707 0.010 29.304 <0.001
CYP51A1 5.565 0.135 14.043 0.003 16.604 0.011 8.678 0.034 1.282 0.733 9.751 0.021 20.433 0.015 9.702 0.138 7.795 0.254
Significant values are highlighted in bold.
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Figure 4: Unsupervised hierarchical cluster analysis of oxysterol metabolising enzymes. Graphical representation of the 
immunohistochemistry marker data is shown in the left hand panel. The right hand panel shows the results of the hierarchical cluster 
analysis presented as a dendrogram with 5 individual clusters identified. Oxysterol metabolising enzymes are represented in columns and 
individual cases in rows.
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information about tumour stage, lymph node involvement 
or extramural venous invasion. In this case oxysterol 
metabolising enzyme signature was highly significant 
in both the whole patient cohort (p=0.002, HR=1.791, 
95% CI 1.236-2.595) and the mismatch repair proficient 
group (p=0.011, HR=1.703, 95% CI, 1.129-2.568) 
(Supplementary Table 9).
The relationship of individual oxysterol 
metabolising enzymes, clinico-pathological 
parameters and survival
The relationship between expression of each protein 
and overall survival was investigated using different cut-
off points of immunostaining intensity to allow a total 
Table 3: The relationship between cluster groups and pathological parameters in the whole patient cohort, mismatch 
repair proficient cohort and mismatch repair deficient cohort
Screen 
detected  
(yes v no)
Tumour 
site (colon v 
rectum)
Tumour site 
(proximal 
colon v distal 
colon v 
rectum)
Tumour 
differentiation 
(well/
moderate v 
poor)
EMVI 
(present or 
absent)
Mismatch 
repair 
protein status 
(proficient v 
deficient)
Tumour stage Lymph node 
stage
Dukes stage
Cluster 
group 1 
v cluster 
group 2
χ2 p-value χ2 p-value χ2 p-value χ2 p-value χ2 p-value χ2 p-value χ2 p-value χ2 p-value χ2 p-value
Whole 
patient 
cohort
4.298 0.038 0.389 0.533 4.122 0.127 0.109 0.742 0.336 0.562 0.035 0.851 13.597 0.004 10.091 0.006 21.057 p<0.001
Mismatch 
repair 
proficient 
tumours
3.527 0.06 0.356 0.551 4.014 0.134 0.143 0.705 0.474 0.491 - - 10.465 0.015 9.889 0.007 17.465 p<0.001
Mismatch 
repair 
deficient 
tumours
0.043 0.837 0 1 1.364 0.506 0.274 0.600 0 1 - - 0.357 0.949 0.014 0.993 0.211 0.900
Significant values are highlighted in bold.
Table 4: The relationship between cluster groups and individual oxysterol metabolising enzymes in the whole patient 
cohort, mismatch repair proficient cohort and mismatch repair deficient cohort
Whole patient cohort Mismatch repair proficient cohort Mismatch repair deficient 
cohort
χ2 p-value Expression in 
cluster group 1 
v group 2
χ2 p-value Expression in 
cluster group 1 
v group 2
χ2 p-value Expression in 
cluster group 
1 v group 2
CYP2R1 14.716 0.002 Low 9.847 0.02 Low 6.189 0.103 Low
CYP7B1 6.322 0.097 High 6.744 0.081 High 0.888 0.828 High
CYP8B1 75.659 <0.001 Low 56.049 <0.001 Low 19.408 <0.001 Low
CYP27A1 9.075 0.028 Low 6.316 0.097 Low 2.499 0.475 Low
CYP39A1 5.58 0.061 Low 6.844 0.03 Low 0.911 0.634 Low
CYP46A1 57.653 <0.001 Low 58.387 <0.001 Low 2.436 0.487 Low
CYP51A1 46.945 <0.001 High 40.233 <0.001 High 7.377 0.061 High
Significant values are highlighted in bold.
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Figure 5: Survival analysis of individual clusters, A. 5 clusters identified by hierarchical cluster analysis, B. The clusters classified 
into two groups (group 1=cluster 1 and group 2 = clusters 2-5 in the whole patient cohort, C. mismatch repair proficient cohort and 
D. mismatch repair deficient cohort.
Table 5: The significance of cluster group in multivariate analysis for the whole patient cohort and mismatch repair 
proficient cohort 
Model A
Whole patient cohort Mismatch repair proficient cohort
Variable (categories) Wald value p-value Hazard ratio (95% 
CI)
Wald value p-value Hazard ratio (95% 
CI)
Age (< 70 v ≥ 70) 29.338 <0.001 1.976 (1.545-2.528) 23.283 <0.001 1.948 (1.486-2.553)
Tumour site  
(colon v rectum)
0.618 0.432 1.119 (0.846-1.481) 0.033 0.829 1.034 (0.764-1.3999)
EMVI  
(present v absent)
42.228 <0.001 2.366 (1.826-3.065) 36.257 <0.001 2.444 (1.827-3.268)
Dukes stage  
(A v B v C)
50.878 <0.001 0.350 (0.231-0.548) 23.030 <0.001 0.387 (0.25-0.645)
Cluster group  
(group 1 v group 2)
5.417 0.02 1.554 (1.072-2.252) 4.103 0.043 1.530 (1.014-2.310)
Model A includes Dukes stage as the parameter for assessing overall tumour stage. 
Significant values are highlighted in bold.
Oncotarget46518www.impactjournals.com/oncotarget
of four comparisons to be made (negative v weak v 
moderate v strong, negative v positive, negative/weak v 
moderate/strong and negative/weak/moderate v strong). 
Supplementary Tables 2-8 details the association between 
each oxysterol metabolising enzyme and overall patient 
survival, using each comparison of immunoreactivity. 
Supplementary Figures 1-3 show the relationship of 
survival and individual oxysterol metabolising enzymes 
in the whole patient cohort, mismatch repair proficient 
tumours and mismatch repair deficient tumours.
Expression of CYP8B1 was consistently associated 
with patient survival. Considering each CYP8B1 intensity 
as a distinct group, increasing intensity was related 
to poorer prognosis (HR=1.191, 95% CI=1.074-1.32, 
χ2=14.97, p=0.002). The mean survival in patients with 
tumours that did not express CYP8B1 (n=201) was 128 
months (95% CI 113-141), declining to 119 months 
(95% CI 104-134) for tumours with weak CYP8B1 
immunostaining (n=171). The mean survival for 
CYP8B1 moderately expressing tumours (n=133) was 
101 months (95% CI 89-113) and the mean survival for 
CYP8B1 strongly expressing tumours (n=118) was 79 
months (95% CI 67-91). When negative/weak staining 
for CYP8B1 was compared to moderate/strong staining, 
there was a statistically significant relationship between 
CYP8B1 expression and survival (HR=1.376, 95% 
CI=1.093-1.731, χ2=7.511, p=0.006). The mean survival 
in patients with tumours showing negative/weak CYP8B1 
immunoreactivity (n=371) was 126 months (95% CI 115-
136) compared to 91 months (95% CI 82-99) in patients 
with tumours showing moderate/strong immunoreactivity 
(n=251). Comparing CYP8B1 negative/weak/moderate 
tumours with CYP8B1 strongly expressing tumours 
demonstrated a highly significant relationship with 
survival (HR=1.649, 95% CI=1.268-22.145, χ2=14.298, 
p<0.001). Patients with strongly staining tumours for 
CYP8B1 (n=118) survived a mean of 79 months (95% 
CI 67-91) whereas negative/weak/moderate CYP8B1 
immunostaining was associated with a better prognosis 
and a mean survival of 123 months (95% CI 114-132).
CYP27A1 expression was associated with patient 
outcome in three out of four comparisons. Considering 
each CYP27A1 stain intensity separately, expression 
was significantly associated with survival (HR=1.144, 
95% CI=0.986-1.328, χ2=7.863, p=0.049). Patients with 
strongly scoring tumours for CYP27A1 (n=16) had 
decreased survival, with a mean survival of 59 months 
(95% CI 35-84) in this group. For CYP27A1 negative 
tumours (n=367) the mean survival was 118 months 
(95% CI 108-128), for CYP27A1 weakly stained tumours 
(n=195) the mean survival was 108 months (95% CI 96-
120) and for CYP27A1 moderately stained (n=44) tumours 
the mean survival was 91 months (95% CI 71-111). When 
negative/weak CYP27A1 immunostaining was compared 
to moderate/strong immunostaining, higher intensities of 
staining were significantly associated with poorer survival 
(HR=1.425, 95% CI=1.006-2.02, χ2=4.038, p=0.044). The 
mean survival in patients with tumours showing moderate/
strong staining for CYP27A1 (n=60) was 82 months (95% 
CI 65-98) whereas for negative/weak tumours (n=562) 
the mean survival was 119 months (95% CI 110-127). 
Investigating strong CYP27A1 immunostaining compared 
to all other stain intensities was also significantly 
associated with survival (HR=2.093, 95% CI=1.2-3.651, 
Table 6: The significance of cluster group in multivariate analysis for the whole patient cohort and mismatch repair 
proficient cohort
Model B
Whole patient cohort Mismatch repair proficient cohort
Variable (categories) Wald value p-value Hazard ratio  
(95% CI)
Wald value p-value Hazard ratio  
(95% CI)
Age (< 70 v ≥ 70) 25.808 <0.001 1.901 (1.484-2.435) 20.958 <0.001 1.887 (1.438-2.477)
Tumour site  
(colon v rectum)
0.454 0.501 1.102 (0.831-1.462) 0.026 0.871 1.026 (0.756-1.392)
EMVI  
(present v absent)
24.777 <0.001 1.973 (1.510-2.579) 21.311 <0.001 2.038 (1.507-2.758)
Tumour stage  
(pT1 v pT2 v pT3 v pT4)
21.681 <0.001 0.363 (0.223-1.091) 14.770 0.002 0.569 (0.217-1.243)
Lymph node stage (pN0 
v pN1 v pN2)
57.291 <0.001 0.296 (0.216-0.765) 34.912 <0.001 0.341 (0.238-0.826)
Cluster group  
(group 1 v group 2) 4.522 0.033 1.497 (1.032-2.172) 2.911 0.088 1.434 (0.948-2.170)
Model B include tumour (pT) stage and lymph node (pN) stage as the parameters for assessing overall tumour stage.
Significant values are highlighted in bold.
Oncotarget46519www.impactjournals.com/oncotarget
χ2=7.135, p=0.008). Strong CYP27A1 immunostaining 
(n=16) resulted in a mean survival of 59 months (95% 
CI 35-84) compared to 118 months (95% CI 109-126) for 
negative/weak/moderate staining for CYP27A1 (n=606).
Immunohistochemistry for CYP39A1 did not reveal 
any strong staining. In a comparison of negative versus 
weak versus moderate staining for CYP39A1, a highly 
statistically significant association with survival was 
identified (HR=1.533, 95% CI=1.237-1.898, χ2=25.144, 
p<0.001). Tumours showing negativity for CYP39A1 
(n=453) were associated with a mean survival of 125 
months (95% CI 115-134), for CYP39A1 weakly stained 
tumours (n=164) the mean survival was 89 months (95% 
CI 79-99) and for CYP39A1 moderately stained tumours 
(n=12) the mean survival was 33 months (95% CI 16-
50). Comparing CYP39A1 negatively staining tumours 
versus CYP39A1 positively staining tumours, CYP39A1 
expression demonstrated a statistically significant 
relationship with survival (HR=1.468, 95% CI=1.157-
1.861, χ2=10.21, p=0.001). Patients whose tumours did 
not express CYP39A1 (n=453) had a mean survival of 
125 months (95% CI 115-135) whereas patients with 
weak/moderate staining for CYP39A1 (n=176) had a 
mean survival of 86 months (95% CI 76-96). Comparing 
negative/weakly stained tumours for CYP39A1 with 
moderately stained tumours revealed a highly significant 
relationship between expression and survival (HR=3.514, 
95% CI=1.917-6.440, χ2=18.974, p<0.001). The mean 
survival for CYP39A1 negative/weak staining tumours 
(n=617) was 117 months (95% CI 109-126), declining to 
33 months (95% CI 17-50) for patients whose tumours 
demonstrated moderate immunostaining for CYP39A1 
(n=12).
Overall expression of CYP46A1 considering 
negative, weak, moderate and string staining as separate 
groups showed a statistically significant relationship with 
survival (HR=1.151, 95% CI=1.021-1.296, χ2=8.515, 
p=0.036). Tumours that were negative for CYP46A1 
(n=74) showed a mean patient survival of 117 months 
(95% CI 95-138), weakly stained tumours (n=173) had 
a mean survival of 128 months (95% CI 113-144) and 
moderately stained tumours (n=205) had a mean survival 
of 113 months (95% CI 100-126). Strong staining reflected 
a poorer outcome, with patients who had strongly staining 
tumours for CYP46A1 (n=173) surviving a mean of 87 
months (95% CI 76-98). A comparison of strong CYP46A1 
immunostaining versus all other stain intensities was also 
significantly associated with survival (HR=1.422, 95% 
CI=1.115-1.813, χ2=8.179, p=0.004). In common with all 
other associations noted, higher CYP46A1 expression was 
linked to poorer prognosis. Tumours demonstrating strong 
CYP46A1 immunostaining (n=173) had a mean patient 
survival of 87 months (95% CI 76-98) whereas negative/
weak/moderate CYP46A1 immunostaining (n=452) was 
associated with a mean patient survival of 122 months 
(95% CI 112-131).
DISCUSSION
Colorectal cancer is one of the commonest types 
of solid tumour worldwide with an incidence that is still 
increasing especially in specific geographic areas [1]. 
While the molecular pathways involved in the initiation 
and the early stages of the development of colorectal 
cancer have been well defined this type of tumour still 
has a relatively poor prognosis with an overall survival 
of about 50-60%. The introduction of screening programs 
for its earlier detection and the development of targeted 
therapies for locally advanced and metastatic disease 
should impact on and improve the outcome from this 
disease [2, 19]. However, there is still a clear requirement 
to identify biomarkers of colorectal cancer which can 
contribute to improved screening and earlier diagnosis and 
prognostic stratification [3, 20].
This study has identified the expression profile of 
oxysterol metabolising enzymes in a well-characterised 
uniform cohort of primary colorectal cancers none of 
which had received pre-operative chemotherapy and/or 
radiotherapy. The expression of each enzyme was studied 
in primary colorectal cancer, corresponding lymph node 
metastasis and normal colonic mucosa. An oxysterol 
metabolising enzyme expression profile or signature 
associated with prognosis was identified.
Oxysterol metabolising enzymes are members of the 
cytochrome P450 superfamily of enzymes which catalyse 
NADPH-dependent mono-oxygenation reactions [21]. The 
cytochromes P450s are generally considered to belong to 
one of two distinct groups depending on whether they 
metabolise xenobiotics or endogenous substances and are 
classified into families, subfamilies and individual forms 
according to sequence homology and substrate specificity 
[22-25]. The major xenobiotic metabolising cytochrome 
P450s are members of the CYP1, CYP2 and CYP3 
families. There is extensive evidence for the expression 
of xenobiotic metabolising enzymes in tumours [26-29]. 
There was no evidence of intra-tumour heterogeneity 
and this is consistent with our previous studies of other 
cytochrome P450 enzymes in tumours [29, 30, 31]. With 
some cytochrome P450s especially CYP1B1 showing 
increased expression in tumour cells and the tumour 
associated expression of individual cytochrome P450s has 
been exploited as therapeutic targets for P450 mediated 
pro-drug activation and as a cancer vaccine [29, 32-
34]. The cytochrome P450s involved in the metabolism 
of a diverse range of endogenous compounds including 
eicosanoids, fatty acids, steroids and vitamins are the 
CYP4 family and higher numbered cytochrome P450 
families.
Oxysterols are derived from cholesterol and can 
be produced by the hydroxylation of cholesterol by 
specific cytochrome P450 enzymes [35, 36]. Tumour-
derived oxysterols are multifunctional lipid-signalling 
molecules and recent evidence indicates that they 
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have pleiotropic effects in tumours [9]. Individual 
oxysterols have been identified as having a variety of 
functions in tumours including influence on tumour cell 
proliferation and tumour growth, mediating the tumour 
microenvironment especially of immune cell function 
and inflammation, tumour invasion and metastasis via 
the matrix metalloproteinase system and also mediating 
tumour associated angiogenesis [7, 12, 14, 16, 37]. The 
overall influence of oxysterols on tumour biology will 
depend on the relative expression of individual oxysterol 
metabolising enzymes. Although this study has focused on 
oxysterol pathway and its influence in tumour progression 
and metastasis, it is worth noting that cytochrome P450 
enzymes have pleotropic functions that might also impact 
on tumour progression by modulating other signalling 
pathways.
In this study monoclonal antibodies with specificity 
for individual oxysterol metabolising enzymes CYP2R1, 
CYP7B1, CYP8B1, CYP27A1, CYP39A1, CYP46A1 and 
CYP51A1, have been produced. Peptides to C-terminal 
amino acid sequences identified on the basis of sequence 
alignment and homology modelling of individual 
cytochrome P450s were used as immunogen as this 
approach has proved highly successful in the development 
of monoclonal antibodies selective for individual 
cytochrome P450s [26].
CYP2R1, CYP7B1, CYP8B1, CYP46A1 and 
CYP51A1 all showed significantly increased expression 
in primary colorectal cancer compared to normal colonic 
mucosa with CY7B1 demonstrating the highest proportion 
of strong immunoreactivity in colorectal cancer compared 
to all other enzymes studied. This is the first study to 
analyse the expression of CYP7B1 in colorectal cancer, 
with previous research focusing on expression levels in 
prostate and breast cancer due to the role of CYP7B1 
in sex hormone metabolism [38, 39]. CYP7B1 has been 
shown to be associated with survival in both breast cancer 
and prostate cancer [36, 37]. The findings of increased 
expression of CYP8B1 and CYP46A1 in primary 
colorectal cancer are novel findings. This study found 
increased expression of CYP51A1 in primary colorectal 
cancer compared with normal colonic mucosa. This 
finding is consistent with a previous study that also found 
increased expression of CYP51A1 in primary colorectal 
cancer [28].
Hierarchical cluster analysis allows the unbiased 
identification of groups of cases with similar expression 
profiles. Cluster analysis of the whole patient cohort 
identified five clusters which were mapped to two groups 
that were of prognostic significance; a good prognosis 
group which demonstrated low expression of CYP2R1, 
CYP8B1, CYP27A1, and CYP46A1 in comparison to their 
expression in the poor prognosis group. Similar prognostic 
potential of CYP27A1 and CYP7B1 in breast cancer 
has been reported [18, 38]. That research highlighted 
the important roles played by the oxysterol metabolite 
27-hydroxycholesterol which results from both anabolism 
and catabolism of CYP27A1 and CYP7B1 enzymes 
respectively in tumour pathophysiology. The fact that 
our study has examined all the key enzymes of oxysterol 
pathway in colorectal cancer will lead to a comprehensive 
understanding of roles played by such enzymes and their 
oxysterol metabolites in tumour. Multi-variate analysis 
confirmed independent prognostic significance. Of 
particular interest was the highly significant prognosis 
in a model containing only information available at the 
time of biopsy diagnosis of colorectal cancer. This is 
important as the concept is emerging of treating more 
patients diagnosed with colorectal with neoadjuvant 
therapy followed by either observational follow-up or 
salvage surgery and it will be essential to have prognostic 
or risk-stratification biomarkers for this scenario in which 
only tumour biopsies are available for study at the time of 
initial treatment decisions [40].
The mismatch repair pathway is one of the major 
pathways of colorectal cancer development [41, 42]. 
Tumours that lack key mismatch repair proteins are 
classified as mismatch repair defective or deficient or 
unstable. Those patients with mismatch repair deficient 
tumours are already regarded as a distinct subgroup in 
selecting patients for adjuvant therapy and indicating 
prognosis, therefore the mismatch repair proficient group 
are of particular interest. For example, recent studies 
indicate that mismatch repair deficient tumours respond 
to immune checkpoint anti-programmed cell death 
1 inhibitors in contrast to mismatch repair proficient 
tumours which showed no response [43]. This is due 
to the fact that mismatch repair deficient tumours have 
a high mutational load in coded proteins increasing the 
probability of recognition and elimination by the immune 
system. On the other hand, mismatch repair proficient 
tumours have low mutational load, proving effective in 
evading immune system. If this is the case then it is very 
plausible to speculate that most of existing and ongoing 
immunotherapies, including anti-CTLA4 and anti-
CD20 will have limited therapeutic effect on mismatch 
repair proficient CRC patients. It is well-established that 
mismatch repair proficient tumours represent the majority 
of colorectal cancer patients and frequently has a worse 
prognosis compared to mismatch repair deficient tumours 
hence in most need of novel therapies. In the mismatch 
repair proficient group, a protein signature was identified 
that was associated with prognosis. This reflected the same 
relative expression of each cytochrome P450 as the whole 
patient cohort good prognosis group compared to the poor 
prognosis group. In the mismatch repair deficient group 
there was also a trend towards poorer prognosis.
This study also assessed the phenotypic expression 
of each P450 in both primary colorectal cancer and 
paired lymph node metastasis. When the primary 
tumours of lymph node positive cases (Dukes C, stage 
3) were compared to the paired lymph node metastasis, 
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expression of CYP2R1, CYP8B1, CYP39A1, CYP46A1 
and CYP51A1 were each significantly reduced in the 
lymph node metastasis. This highlights the role of the 
tumour microenvironment in influencing the expression 
of the target proteins, a concept increasingly recognised 
in studies of the metastatic spread of malignancy [44-46]. 
The findings of this study have provided further evidence 
of the potential role of the tumour microenvironment 
in altering the phenotype of cancer cells. The spatial 
organization and hence interactions of individual types 
of immune cells within lymph nodes are distinct from 
the microenvironment of the primary tumour and thus 
contributes to a microenvironment that has a different 
structure and function to that of the primary tumour 
[47]. The variation in phenotype observed in metastasis 
compared to the primary malignancy also highlights 
the difficulty in effectively treating metastatic disease. 
Treatments for metastatic disease are often guided by 
assessment of the primary tumour which, as confirmed 
by this study, does not necessarily reflect phenotypic 
expression of disease at metastatic sites.
In conclusion this study has defined the expression 
of oxysterol metabolising P450s in a well-characterised 
cohort of colorectal cancers. An oxysterol metabolizing 
enzyme signature has been identified which is associated 
with prognosis in the whole patient cohort and the 
mismatch repair proficient cohort. This good prognosis 
group showed tumours with low expression of CYP2R1, 
CYP8B1, CYP27A1 and CYP46A1 relative to the poor 
prognosis group and a schematic model of the relationship 
of oxysterol metabolizing enzymes in good and poor 
prognosis colorectal cancers is outlined in Figure 6. This 
study also raises the possibility of therapeutic targeting of 
the oxysterol metabolising pathway as individual P450s 
are well-characterised actionable drug targets [48].
MATERIALS AND METHODS
Monoclonal antibodies
Monoclonal antibodies to individual oxysterol 
metabolising enzymes (CYP2R1, CYP7B1, CYP8B1, 
CYP27A1, CYP39A1, CYP46A1, and CYP51A1) were 
developed in collaboration with Vertebrate Antibodies 
Ltd (Aberdeen, UK) using synthetic peptides. Peptides 
within the protein sequences were selected from regions 
which were antigenic, exposed on the surface and 
unique to the target protein [26, 49-51]. The amino acid 
sequences and location on the proteins are indicated in 
Table 7. The peptides were obtained from Almac Sciences 
Ltd, (Edinburgh, UK) and conjugated individually to 
ovalbumin for the immunisations and to bovine serum 
albumin for the ELISA test [50, 52]. The immunisation of 
mice, production of hybridoma cells and ELISA screening 
were carried out essentially as described previously except 
that the antigen was given by subcutaneous route [47]. The 
hybridomas were cloned by limiting dilution until a single 
ELISA positive colony was grown in a 96 well plate. 
Individual cell lines were then grown at high cell density 
for the preparation of the antibody stock which was used 
Figure 6: An overview of oxysterol metabolising enzymes in good and poor prognostic colorectal cancers. A. Good 
prognosis colorectal cancers. CYP51A1, CYP27A1, CYP2R1, CYP46A1, CYP39A1 and CYP8B1 expression profile is low. This results in 
a lower concentration of oxysterols. Low oxysterol levels have less impact on promoting tumour invasion, metastasis, tumour cell survival 
and growth leading to a better survival outcome. However, increased expression of CYP7B1 correlates with good prognosis and this has 
been observed in breast cancer and prostate cancer. B. Poor prognosis colorectal cancers. CYP51A1, CYP27A1, CYP2R1, CYP46A1, 
CYP39A1 and CYP8B1 expression is increased in comparison with good prognostic tumours. This results in a significant increase in 
oxysterols. Oxysterols promote invasion and metastasis through LRX target genes and facilitates tumour cell survival and growth through 
immune system evasion and chemo-attraction of proangiogenic neutrophils.
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subsequently for their characterisation by immunoblotting 
and immunohistochemistry. All the antibodies are now 
commercially available from Vertebrate Antibodies.
Immunoblotting
Whole cell lysates from cells (human embryonic 
kidney cells-HEK 293) overexpressing CYP2R1, 
CYP7B1, CYP8B1, CYP27A1, CYP39A1, CYP46A1 and 
CYP51A1 respectively were used as positive controls for 
immunoblotting while lysates from cells containing vector 
only were used as negative controls. The cell lysates and 
their corresponding controls were obtained from (Novus 
Biologicals, Cambridge, UK). Cell lysates (5 μg protein/
lane) were resolved by electrophoresis on NuPAGE 4-12% 
Bis-Tris gels (Fisher Scientific, Loughborough, UK). 
Following protein transfer to nitrocellulose membrane 
the membranes were washed for 45 minutes at room 
temperature in phosphate buffered saline-Tween-20 
(PBST) containing 3 % (w/v) skimmed milk powder to 
block non-specific protein binding. Membranes were 
incubated overnight at 4°C with individual monoclonal 
antibodies diluted in PBST (1/2 dilution) and then washed 
6 times for a total of 60 minutes in 1% skimmed milk. The 
membranes were subsequently probed for 60 minutes with 
a secondary antibody conjugated horseradish-peroxidase-
conjugated anti-mouse IgG (1/2000, Sigma-Aldrich, 
Dorset, UK). Membranes were then washed (6 times) for 
a total of 60 minutes in 1% skimmed milk and protein 
bands visualized using the enhanced chemiluminescence 
detection system (Fisher Scientific) [26, 49].
Colorectal cancer tissue microarray
The patient cohorts of mismatch repair proficient 
and deficient colorectal cancers included 650 patients 
with a histologically confirmed diagnosis of primary 
colorectal cancer. All patients had undergone elective 
surgery for primary colorectal cancer, at Aberdeen Royal 
Infirmary (Aberdeen, UK), between the years of 1994 
and 2009. Any patients who had received neoadjuvant 
chemotherapy and/or radiotherapy were excluded. 
Tissue was obtained retrospectively from the Aberdeen 
Colorectal Tumour Bank the Grampian Biorepository 
(www.biorepository.nhsgrampian.org), Aberdeen, UK 
provides governance for this tissue bank, see ethics 
statement). Survival information, in the form of all-cause 
mortality (i.e. overall survival), was available for each 
patient. At the time of censoring patient outcome data 
there had been 309 (47.5%) deaths. The mean patient 
survival was 115 months (95% CI 108-123 months). The 
study was conducted according to REMARK criteria and 
clinico-pathological characteristics of the patients and 
their tumours and relationship with survival are detailed 
in Table 8 and Supplementary Table 1.
The histopathological reporting of the tumours was 
conducted in line with The Royal College of Pathologists 
UK guidelines for the histopathological reporting of 
colorectal cancer resection specimens and incorporating 
guidance from TNM5 [53]. The histopathological processing 
of the colorectal cancer excision specimens is detailed in 
Supplementary information Materials and Methods S1.
A tissue microarray was constructed as described 
from blocks of formalin fixed, paraffin embedded 
tissue specimens and included 650 primary colorectal 
cancers, 285 lymph node metastasis and 50 samples of 
morphologically normal colonic mucosa obtained from 
resection specimens at a site at least 10cm distant from the 
tumour [26, 54, 55]. Two cores each measuring 1mm in 
diameter were examined per primary tumour, lymph node 
and normal tissue sample as detailed in the Supplementary 
information Materials and Methods S1.
Immunohistochemistry
Immunohistochemistry for each antibody was 
carried out using the Dako EnVision™ system (Dako, Ely, 
UK) using a Dako autostainer as previously described [26, 
49, 54]. Sections were soaked in xylene to remove paraffin 
then rehydrated in alcohol prior to immunohistochemistry. 
When required (CYP7B1, CYP27A1, CYP39A1, 
CYP46A1 and CYP51A1), antigen retrieval was 
Table 7: Peptide sequences used as immunogens to generate monoclonal antibodies
Enzyme Hybridoma clone Peptide sequence Amino acid location
CYP2R1 M26P6H1 QPYLICAERR 492–501
CYP7B1 M17P3F2 IQYPDSDVL 491–499
CYP8B1 M15P3B7 QPSHDVRFR 486– 494
CYP27A1 V29P4B8*B2 KVVLAPETGEL 498–508
CYP39A1 M30P6D6 CRIEYKQRI 461–469
CYP46A1 N8P6E4*H8 PVLCTLRPR 481–489
CYP51A1 N6P2H5*G8 NPVIRYKRRS 493–502
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Table 8: Clinico-pathological characteristics of all patients and their tumours and the relationship of each variable 
with overall survival
Characteristic Number of 
patients
Percentage Relationship with overall survival
Sex
 Male 340 52.3 χ2= 0.027, p=0.870
 Female 310 47.7
Age
 <70 305 46.9 χ2=29.213, p<0.001
 ≥70 345 53.1
Screen detected
 Yes 52 8 χ2=16.381, p<0.001
 No 598 92
Tumour site
 Proximal colon 261 40.2 Proximal v distal, χ2= 8.418, p=0.004
 Distal colon 245 37.7 Distal v rectal, χ2= 0.906, p=0.341
 Rectum 144 22.2 Colon v rectum, χ2=0.098, p=0.754
Tumour differentiation
 Well/moderate 600 92.3 χ2=0.976, p=0.323
 Poor 50 7.7
Extra mural venous invasion
 Present 140 21.5 χ2=100.946, p<0.001
 Absent 510 78.5
Mismatch repair protein status
 Defective 96 15.2 χ2=2.848, p=0.091
 Proficient 536 84.8
Tumour (pT) stage
 pT1 30 4.6 T1 v T2, χ2=0.382, p=0.536
 pT2 114 17.5 T2 v T3, χ2=24.739, p<0.001
 pT3 411 63.2 T3 v T4, χ2=30.159, p<0.001
 pT4 95 14.6
Lymph node (pN) stage
 pN0 364 56 N0 v N1, χ2=54.071, p<0.001
 pN1 177 27.2 N1 v N2, χ2=17.636, p<0.001
 pN2 109 16.8
Dukes stage
 A 120 18.5 A v B, χ2=5.059, p=0.025
 B 244 37.5 B v C, χ2=65.510, p<0.001
 C 286 44
Significant values are highlighted in bold.
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performed by microwave oven heating in a citrate buffer 
solution. Slides were fully immersed in pre-heated citrate 
buffer (pH 6) then heated in an 800W microwave at full 
power for 20 minutes. The slides were then allowed to 
cool at room temperature and placed in cold running water 
to complete the cooling process. Antigen retrieval was 
not required for monoclonal antibodies to CYP2R1 and 
CYP8B1.
The initial step in the automated staining protocol 
was a wash buffer rinse (Dako). Next, slides were 
incubated with the primary antibody for 60 minutes then 
washed with buffer. Each primary antibody was applied 
as undiluted tissue culture supernatant. Slides were then 
washed in buffer and peroxidase enzyme block was 
applied for a period of 7 minutes and slides were then 
again rinsed with wash buffer. Subsequently, the pre-
diluted peroxidase labelled polymer coupled to goat 
anti-mouse/rabbit secondary antibody was applied for 30 
minutes then rinsed with buffer to remove any unbound 
antibody. The diaminobenzidine (DAB) substrate was then 
applied for 7 minutes to demonstrate sites of peroxidase 
activity before a final wash with buffer then water. Slides 
were immersed in 0.5% copper sulphate for 2 minutes 
to intensify the DAB stain then washed with running 
water. Finally, slides were immersed in filtered Harris 
haematoxylin to lightly counterstain the nuclei before 
being dehydrated in alcohol and xylene and mounted. 
Omitting the primary monoclonal antibody from the 
immunohistochemical procedure and replacing it with 
antibody diluent (Dako) acted as a negative control. 
Normal liver was used as a positive control for CYP2R1, 
CYP7B1, CYP8B1, CYP39A1, CYP46A1 and CYP51A1. 
Grade 3 breast cancer of no special type was used a 
positive control for CYP27A1.
Immunohistochemistry was also performed on 
whole sections of a sub-set of tumours to investigate 
possible intra-tumour heterogeneity. Sections from the 
same tissue blocks from which tissue cores were obtained 
were used.
Following the completion of the 
immunohistochemistry protocol, the slides were examined 
by light microscopy using an Olympus BX 51 light 
microscope (Olympus, Southend-on-Sea, Essex, UK) 
equipped with an Olympus C4040 camera (Olympus). 
The intensity of immunostaining was quantified using a 
semi-quantitative scoring method as previously described 
[26, 49, 54]. The intensity of immunostaining (negative, 
weak, moderate, strong) and its localisation (cytoplasmic, 
nuclear, membranous) was assessed in the first instance by 
one investigator (RS). Following this primary scoring, a 
second investigator (GIM) independently scored each pair 
of cores. In the case of any discrepancies (less than 5 % 
of cases, kappa=0.931), both investigators simultaneously 
re-assessed the core in order to reach an agreed score. The 
highest scoring core for each individual tissue sample was 
recorded.
Assessment of mismatch repair protein status
Mismatch repair protein status had previously been 
assessed by immunohistochemistry using antibodies to 
MLH1 and MSH2 [26]. Mismatch repair protein status 
was recorded as either proficient or defective.
Statistics
Statistical analysis of the data including the Mann-
Whitney U test, Wilcoxon signed rank test, chi-squared 
test, Kaplan-Meier survival analysis, log-rank test and Cox 
multi-variate analysis (variables entered as categorical 
variables) including the calculation of hazard ratios and 
95% confidence intervals was performed using IBM SPSS 
version 22 for Windows 7™ (IBM, Portsmouth, UK). The 
log rank test was used to determine survival differences 
between individual groups. A probability value of p≤0.05 
was regarded as significant. The influence of different 
cut-off points in relation to survival was investigated by 
dichotomising the immunohistochemistry intensity score 
for each marker. The groups that were analysed were 
negative staining versus any positive staining, negative 
and weak staining versus moderate and strong staining 
and negative, weak and moderate staining versus strong 
staining.
Unsupervised hierarchical cluster analysis was 
carried out using the within-group average linkage method 
with Pearson correlation as the cluster measure and cluster 
analysis was performed without any transformation of the 
data or imputation of missing values.
Ethics
The colorectal cancer tissue microarray is held 
under the auspices of the Grampian Biorepository which 
has delegated research ethics authority (11/NS/0015) 
from The North of Scotland research ethics committee 
to approve research projects involving human tissue 
and data. This project was approved by the Grampian 
Biorepository scientific access group committee (Tissue 
request No. 0002). Written consent for the formalin fixed 
wax embedded tissue samples included in the colorectal 
cancer tissue microarray was not required.
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